Diagnosis, severity, and recovery of attacks in the N-MOmentum study of inebilizumab in Neuromyelitis optica spectrum disorder

被引：0

作者：

Weinshenker, B. ^{[1
]}

Wingerchuk, D. ^{[2
]}

Green, A. ^{[3
]}

Bennett, J. ^{[4
]}

Kim, H. J. ^{[5
]}

Pittock, S. ^{[1
]}

Fujihara, K. ^{[6
]}

Paul, F. ^{[7
,8
,9
,10
]}

Cutter, G. ^{[11
]}

Marignier, R. ^{[12
]}

Aktas, O. ^{[13
]}

Hartung, H. -P. ^{[13
]}

Drappa, J. ^{[14
]}

Barron, G. ^{[15
]}

Madani, S. ^{[14
]}

Ratchford, J. ^{[14
]}

Shi, D. ^{[14
]}

Cimbora, D. ^{[14
]}

Katz, E. ^{[14
]}

Cree, B. ^{[3
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Mayo Clin, Scottsdale, AZ USA

[3] Univ Calif San Francisco, Weill Inst Neurosci, Neurol, San Francisco, CA 94143 USA

[4] Univ Colorado, Sch Med, Neurol & Ophthalmol, Denver, CO USA

[5] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea

[6] Fukushima Med Univ, Sch Med, Fukushima, Japan

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Free Univ Berlin, Berlin, Germany

[9] Humboldt Univ, Berlin, Germany

[10] Berlin Inst Hlth, Berlin, Germany

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Hosp Civils Lyon, Lyon, France

[13] Heinrich Heine Univ, Dusseldorf, Germany

[14] Viela Bio, Gaithersburg, MD USA

[15] Astrazeneca, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P358

引用

页码：137 / 138

页数：2

共 50 条

[21] Inebilizumab prevents neuromyelitis optica spectrum disorder disability: outcomes from the N-MOmentum randomised, placebo-controlled, double-masked trial
Marignier, R.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Green, A.
Aktas, O.
Hartung, H. -P.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 896 - 898
[22] Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Tina Nie
Hannah A. Blair
CNS Drugs, 2022, 36 : 1239 - 1239
[23] Inebilizumab Reduces Worsening Of Disability In Neuromyelitis Optica Spectrum Disorder: Outcomes And Long-term Follow-up Data From The N-MOmentum Trial
Wingerchuk, D.
Marignier, R.
Bennett, J. L.
Kim, H.
Weinshenker, B.
Pittock, S.
Fujihara, K.
Paul, F.
Cutter, G.
Green, A.
Aktas, O.
Hartung, H.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
Cree, B. A.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 106 - 106
[24] Elevated Serum Glial Fibrillary Acidic Protein (sGFAP) is Associated With Increased Risk of Neuromyelitis Optica Spectrum Disorder Attacks in the N-Momentum Randomized, Masked, Placebo-Controlled Clinical Trial of Inebilizumab
Aktas, O.
Smith, M. A.
Rees, W.
Fujihara, K.
Paul, F.
Hartung, H-P
Marignier, R.
Bennett, J. L.
Kim, H. J.
Weinshenker, B. G.
Pittock, S. J.
Wingerchuk, D.
Cutter, G.
Green, A.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
Wang, L.
She, D.
Cimbora, D.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP42 - NP43
[25] Elevated serum glial fibrillary acidic protein (sGFAP) is associated with increased risk of neuromyelitis optica spectrum disorder attacks in the N-MOmentum randomised, masked, placebo-controlled clinical trial of inebilizumab
Aktas, O.
Smith, M.
Rees, W.
Fujihara, K.
Paul, F.
Hartung, H. -P.
Marignier, R.
Bennett, J.
Kim, H. J.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Cutter, G.
Green, A.
Mealy, M.
Drappa, J.
Barron, G.
Madani, S.
Wang, L.
She, D.
Cimbora, D.
Ratchford, J.
Katz, E.
Cree, B.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 901 - 902
[26] Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Weinshenker, Brian G.
Wingerchuk, Dean M.
Green, Ari J.
Bennett, Jeffrey L.
Kim, Ho Jin
Pittock, Sean J.
Fujihara, Kazuo
Paul, Friedemann
Cutter, Gary
Marignier, Romain
Aktas, Orhan
Hartung, Hans-Peter
She, Dewei
Smith, Michael
Rees, William
Patterson, Kristina
Cimbora, Daniel
Katz, Eliezer
Cree, Bruce A. C.
N MOmentum Study Investigators
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (08) : 945 - 955
[27] MULTIDIMENSIONAL EVALUATION OF INEBILIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER
Fortunato, A.
Antonini, D.
Basile, M.
Di Brino, E.
Di Pippo, S.
Falasca, G.
Rumi, F.
Cicchetti, A.
VALUE IN HEALTH, 2023, 26 (12) : S348 - S348
[28] Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial
Rensel, Mary
Zabeti, Aram
Mealy, Maureen A.
Cimbora, Daniel
She, Dewei
Drappa, Jorn
Katz, Eliezer
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (06) : 925 - 932
[29] Sensitivity analyses of time to adjudicated attacks in the N-MOmentum study, a randomised, placebo-controlled, double-masked trial in patients with neuromyelitis optica spectrum disorder
Cree, B. A. C.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H. -P.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 928 - 929
[30] The N-MOmentum study - a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results
Cree, B.
Bennett, J.
Kim, H. J.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H. -P.
Lublin, F.
Mealy, M.
Drappa, J.
Barron, G.
Madani, S.
Shi, D.
Cimbora, D.
Rees, W.
Ratchford, J.
Katz, E.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 42 - 44

← 1 2 3 4 5 →